Matrix-Type Transdermal Drug Delivery System of Trandolapril: In Vitro and Ex Vivo Characterization

References

1. 1.↵
   1. Robinson J. R.,
   2. Lee V. H.

   Controlled Drug Delivery: Fundamentals and Applications; 2nd ed.; Marcel Dekker: New York, 1987; pp 523– 552.
2. 2.↵
   1. Kanikannan N.,
   2. Andega S.,
   3. Burton S.,
   4. Babu R. J.,
   5. Singh M.

   Formulation and in vitro evaluation of transdermal patches of melatonin. Drug Dev. Ind. Pharm. 2004, 30 ( 2), 205– 212.

   OpenUrlPubMed
3. 3.↵
   1. Guay D. R. P.

   Trandolapril: A newer angiotensin-converting enzyme inhibitor. Clin. Ther. 2005, 25 ( 3), 713– 775.

   OpenUrl
4. 4.↵
   1. Wiseman L. R.,
   2. McTavish D.

   Trandolapril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994, 48 ( 1), 71– 90.

   OpenUrlPubMed
5. 5.↵
   1. Danielson B.,
   2. Querin S.,
   3. LaRochelle P.,
   4. Sultan E.,
   5. Mouren M.,
   6. Bryce T.,
   7. Stepniewski J. P.,
   8. Lenfant B.

   Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects. J. Cardiovasc. Pharmacol. 1994, 23 ( Suppl 4), S50– S59.

   OpenUrlPubMed
6. 6.↵
   1. Lenfant B.,
   2. Mouren M.,
   3. Bryce T.,
   4. De Lauture D.,
   5. Strauch G.

   Trandolapril: pharmacokinetics of single oral doses in healthy male volunteers. J. Cardiovasc. Pharmacol. 1994, 23 ( Suppl 4) S38– S43.

   OpenUrl
7. 7.↵
   1. Remko M.

   Acidity, lipophilicity, solubility, absorption, and polar surface area of some ACE inhibitors. Chem. Pap. 2007, 61 ( 2), 133– 141.

   OpenUrl
8. 8.↵
   1. Williams A.,
   2. Barry B.

   Terpenes and the lipid-protein partitioning theory of skin penetration enhancement. Pharm. Res. 1991, 8 ( 1), 17– 24.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Okabe H.,
   2. Obata Y.,
   3. Takayama K.,
   4. Nagai T.

   Percutaneous absorption enhancing effect and skin irritation of monocyclic monoterpenes. Drug Des. Deliv. 1990, 6 ( 3), 229– 238.

   OpenUrlPubMed
10. 10.↵
    1. Moghimi H.,
    2. Williams A.,
    3. Barry B.

    A lamellar matrix for stratum corneum intercellular lipids. V. Effects of terpene penetration enhancers on the structure and thermal behaviour of matrix. Int. J. Pharm. 1997, 146 ( 1), 41– 54.

    OpenUrl
11. 11.↵
    1. Gao S.,
    2. Singh J.

    In vitro percutaneous absorption enhancement of lipophilic drug tamoxifen by terpenes. J. Controlled Release 1998, 51 ( 2–3), 193– 199.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Hori M.,
    2. Satoch H.,
    3. Miabach H. I.,
    4. Guy R. H.

    Enhancement effect of propranolol hydrochloride and diazepam skin absorption in vitro: Effect of enhancer lipophilicity. J. Pharm. Sci. 1991, 80 ( 1), 32– 35.

    OpenUrlPubMed
13. 13.↵
    1. Zhao K.,
    2. Singh J.

    In vitro percutaneous absorption enhancement of propranolol hydrochloride through porcine epidermis by terpenes/ethanol. J. Controlled Release 1999, 62 ( 3), 359– 366.

    OpenUrlPubMed
14. 14.↵
    1. Bonina F. P.,
    2. Carellii V.,
    3. Cols G. D.,
    4. Montenegro L.,
    5. Nannipieri E.

    Vehicle effects on in vitro skin permeation of and stratum corneum affinity for model drugs caffeine and testosterone. Int. J. Pharm. 1993. 100 ( 1–3), 41– 47.

    OpenUrlCrossRef
15. 15.↵
    1. Kusum Devi V.,
    2. Saisivum S.,
    3. Maria G. R.,
    4. Deepti P. U.

    Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. Drug Dev. Ind. Pharm. 2003, 29 ( 5), 495– 503.

    OpenUrlPubMed
16. 16.↵
    1. Arora P.,
    2. Mukherjee B.

    Design, development, physicochemical and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. J. Pharm. Sci. 2002, 91 ( 9), 2076– 2089.

    OpenUrlPubMed
17. 17.↵
    1. Gupta R.,
    2. Mukherjee B.

    Development and in vitro evaluation of diltiazem hydrochloride transdermal patches based on povidone-ethyl cellulose matrices. Drug Dev. Ind. Pharm. 2003, 29 ( 1), 1– 7.

    OpenUrlPubMed
18. 18.↵
    1. Suwanpiodokkul N.,
    2. Thongnopnua P.,
    3. Umprayan K.

    Transdermal delivery of zidovidine (AZT): The effects of vehicles, enhancers, and polymer membranes on permeation across cadaver pig skin. AAPS PharmSciTech 2004, 5 ( 3), e48.

    OpenUrlPubMed
19. 19.↵
    1. Krishnaiah Y. S. R.,
    2. Satyanarayana V.,
    3. Karthikeyan R. S.

    Penetration enhancing effect of menthol on the percutaneous absorption of nicardipine hydrochloride from HPC gel through excised rat epidermis. Pharm. Dev. Technol. 2002, 7 ( 3), 305– 316.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Okamoto H.,
    2. Hashida M.,
    3. Sezaki H.

    Structure-activity relationship of 1-alkyl- or 1-alkenylazacycloalkanone derivatives as percutaneous penetration enhancers. J. Pharm. Sci. 1988, 77 ( 5), 418– 424.

    OpenUrlPubMed
21. 21.↵
    1. Williams A. C.,
    2. Barry B. W.

    Terpenes and the lipid-protein-partitioning theory of skin penetration enhancement. Pharm. Res. 1991, 8 ( 1), 17– 24.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Yamune M. A.,
    2. Williams A. C.,
    3. Barry B. W.

    Effects of terpenes and oleic acid as skin penetration enhancer towards 5-fluorouracil as assessed with time; permeation, partitioning and differential scanning calorimetry. Int. J. Pharm. 1995, 116 ( 2), 237– 251.

    OpenUrl
23. 23.↵
    1. Cornwell P. A.,
    2. Barry B. W.

    The routes of penetration of ions and 5-fluorouracil across human skin and the mechanisms of action of terpene skin penetration enhancers. Int. J. Pharm. 1993, 94 ( 1–3), 189– 194.

    OpenUrl
24. 24.↵
    1. Cornwell P. A.,
    2. Barry B. W.,
    3. Stoddart C. P.,
    4. Bouwstra J. A.

    Wide-angle X-ray diffraction of human stratum corneum: Effects of hydration and terpene enhancer treatment. J. Pharm. Pharmacol. 1994, 46 ( 12), 938– 950.

    OpenUrlPubMed
25. 25.↵
    1. Jeevan R. K.,
    2. Venkat R. G.,
    3. Harvy O. B.,
    4. Mansoor A. K.,
    5. Indra K. R.

    Effect of menthol and related terpenes on the percutaneous absorption of propranolol across excised hairless mouse skin. J. Pharm. Sci. 1997, 86 ( 12), 1369– 1373.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Narendra S. J.,
    2. Shekhar B. B.,
    3. Buddhavarapu P. R.,
    4. Arjun R. B.

    Process for the Preparation of Intermediates of Trandolapril and Use Thereof for the Preparation of Trandolapril. US Patent Application Publication No. US#2006/0079698 A1, 2006.
27. 27.↵
    1. Wade A.,
    2. Weller P. J.

    Handbook of Pharmaceutical Excipients; American Pharmaceutical Publishing Association: Washington, DC, 2000; pp 252– 255, 401– 406.
28. 28.↵
    1. Mutalic S.,
    2. Udupa N.

    Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations. J. Pharm. Sci. 2004, 93 ( 6), 1577– 1594.

    OpenUrlPubMed
29. 29.↵
    1. Bodmeier R.,
    2. Paeratakul O.

    Drug release from laminated polymeric films prepared from aqueous latexes. J. Pharm. Sci. 1990, 79 ( 1), 32– 36.

    OpenUrlPubMed
30. 30.↵
    1. Korsmeyer R. W.,
    2. Gurny R.,
    3. Doelker E.,
    4. Buri P.,
    5. Peppas N. A.

    Mechanism of solute release from porous hydrophilic polymers. Int. J. Pharm. 1983, 15, 25– 35.

    OpenUrl
31. 31.↵
    1. Rao P. R.,
    2. Diwan P. V.

    Formulation and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration. Drug Dev. Ind. Pharm. 1998, 24 ( 4), 327– 336.

    OpenUrlPubMed